Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

Professional edition · English
Non-rheumatic conditions · Clinical chapter 01

Rheumatology assessment and ongoing care

Define the rheumatology question, communicate the conclusion and agree who coordinates the next phase.

Olga Goodman, MD · Evidence review: 25 September 2026
On this page
  1. The clinical boundary
  2. What makes a referral useful?
  3. A complete consultation has an exit plan
  4. When to return
  5. What the patient should understand
  6. Sources
Treatment catalogue →

The clinical boundary

A rheumatology referral does not automatically establish ongoing rheumatology care for isolated fibromyalgia, ME/CFS, AMPS or another non-inflammatory condition. Diagnostic assessment, a consultation opinion and an agreed longitudinal treatment relationship are separate tasks. The plan should state which task has been completed and which clinician or service will coordinate the next phase.

The boundary is clinical rather than dismissive. Symptoms may be severe even when the appropriate treatment does not involve rheumatologic immunosuppression. A patient should leave with an explanation and a workable next step, rather than a diagnosis label without a care pathway. Local arrangements and existing care commitments still matter.

What makes a referral useful?

A useful request identifies the suspected disease and the findings that support it: objective joint swelling, a compatible inflammatory pattern, a characteristic rash, progressive proximal weakness, organ abnormalities, or a coherent combination of history, examination and tests. It includes relevant medication exposure, the timeline and the question the referring clinician wants answered.

Widespread pain, fatigue, an isolated positive ANA or dissatisfaction with previous treatment does not by itself establish a need for indefinite rheumatology follow-up. Conversely, normal inflammatory markers cannot universally exclude inflammatory disease. The strength of the clinical phenotype determines the next investigation.

A complete consultation has an exit plan

Document the current working diagnosis, the positive evidence supporting it, important alternatives considered and any unresolved question. Specify who follows outstanding tests. Explain the next treatment targets and identify the intended coordinator: primary care, a pain/rehabilitation service, an ME/CFS-experienced team, neurology, sleep medicine or another appropriate service.

An instruction such as “follow with PCP” is weak if it does not say what the PCP is being asked to manage. A better handoff identifies two or three actionable targets, such as sleep assessment, a time-limited medication trial and a function-oriented rehabilitation plan. Access limitations should be acknowledged in the actual care plan rather than hidden by a nominal referral.

When to return

Reassessment is appropriate when new findings change the clinical question: persistent objectively swollen joints, progressive measured weakness, a compatible new rash with systemic features, renal/hematologic abnormalities, or another coherent signal of inflammatory disease. New severe cardiopulmonary or neurologic symptoms need urgent assessment through the appropriate acute pathway, not a routine return appointment.

Coexisting inflammatory disease creates two concurrent responsibilities. The rheumatologist continues the agreed care for the inflammatory disease; persistent non-inflammatory pain does not automatically justify escalation of immunosuppression. The non-inflammatory symptom plan needs its own coordinator and measurable goals.

What the patient should understand

The consultation has addressed a specific diagnostic question. A non-inflammatory conclusion is a positive direction for care, not a statement that symptoms are imaginary. The next clinician's task and the findings that would justify renewed rheumatologic assessment should be explicit. [1] [2]

Sources and further reading

Original clinical sources; publication language may differ from this guide.

  1. American College of Rheumatology · Fibromyalgia
    Professional society information
  2. HAS · Fibromyalgia in adults: diagnostic process and treatment strategy, 2025
    Guideline
  3. CDC · Evaluation of ME/CFS, updated April 2026
    Clinical information

Olga Goodman, MD · RheumaView™

Copying without attribution prohibited. Educational content; this page is not a clinical messaging service.

Back to the collection

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: Rheumatology